高级检索
当前位置: 首页 > 详情页

Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Aix-Marseille University, Jardin du Pharo, 58 bd Charles Livon, Marseille, 13284 Cedex 07, France. Mondher.Toumi@emaud.eu. [2]Department of Public Health, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille, 13385, France. Mondher.Toumi@emaud.eu. [3]Burnet Institute, 85 Commercial Rd, Melbourne, VIC, 3004, Australia. [4]Hepatitis B Foundation, 3805 Old Easton Rd, Doylestown, PA, 18902, USA. [5]Clarivate (formerly DRG Abacus), 70 St Mary Axe, London, EC3A 8BE, UK. [6]Aspen Consulting, LLC, 625 S Lincoln Ave #101, Steamboat Springs, CO, 80487, USA. [7]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie Fang Avenue, Hankou, Wuhan, 430030, China. [8]National Hospital Organization (NHO) Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki, 856-8562, Japan. [9]Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, 852-8520, Japan. [10]Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. [11]University Hospital of Pisa, Lungarno Pacinotti 43, Pisa, 56126, Italy. [12]Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Liebigstrasse 20, 04103, Leipzig, Germany. [13]Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, 227 South Chongqing Road, Shanghai, 20025, China. [14]Inno Community Development Organisation, Room 208, Dengzheng Business Center, #57, Dengzhengnan Rd, Yuexiu District, Guangzhou, Guangdong, China. [15]Janssen Pharmaceutical K.K, 3-5-2 Nishi-kanda, Chiyoda-ku, Tokyo, 101-0065, Japan. [16]Janssen Pharmaceutica NV, Turnhoutseweg 30, Beerse, B-2340, Belgium. [17]Janssen Research & Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA. [18]Janssen Research & Development, 1400 McKeon Road, Spring House, PA, 19002, USA. [19]Janssen China, 14F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, 100025, China. [20]Janssen Health Economics & Market Access (EMEA), 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK. [21]Janssen Germany, Johnson-u.-Johnson-Platz 1, 41470, Neuss, Nordrhein-Westfalen, Germany. [22]Janssen Italy, Via Michelangelo Buonarroti, 23, Cologno Monzese, 20093, Italy. [23]Janssen Global Services, LLC, 1000 US 202, Raritan, NJ, 08869, USA. echan15@ITS.JNJ.com. [24]Cooperman Barnabas Medical Center, 222 Columbia Turnpike, Florham Park, NJ, 07932, USA.
出处:
ISSN:

关键词: Hepatitis B virus Chronic Hepatitis B Functional cure Qualitative research Self-stigma Social impact

摘要:
People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma.Adults with CHB with a wide range of age and education were recruited from 5 countries and participated in 90-minute qualitative, semi-structured interviews to explore concepts related to CHB-associated stigma and its impact. Participants answered open-ended concept-elicitation questions regarding their experience of social and self-stigma, and the potential impact of reduced CHB-related stigma.Sixty-three participants aged 25 to 71 years (15 from the United States and 12 each from China, Germany, Italy, and Japan) reported emotional, lifestyle, and social impacts of living with CHB, including prejudice, marginalization, and negative relationship and work experiences. Self-stigma led to low self-esteem, concealment of CHB status, and social withdrawal. Most participants stated a functional cure for hepatitis B would reduce self-stigma.CHB-related social and self-stigma are widely prevalent and affect many aspects of life. A functional cure for hepatitis B may reduce social and self-stigma and substantially improve the health-related quality of life of people with CHB. Incorporating stigma into guidelines along with infectivity considerations may broaden the patient groups who should receive treatment.© 2024. The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 2 区 公共卫生、环境卫生与职业卫生
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 公共卫生、环境卫生与职业卫生
JCR分区:
出版当年[2022]版:
Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
最新[2023]版:
Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者单位: [1]Aix-Marseille University, Jardin du Pharo, 58 bd Charles Livon, Marseille, 13284 Cedex 07, France. Mondher.Toumi@emaud.eu. [2]Department of Public Health, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille, 13385, France. Mondher.Toumi@emaud.eu.
通讯作者:
通讯机构: [1]Aix-Marseille University, Jardin du Pharo, 58 bd Charles Livon, Marseille, 13284 Cedex 07, France. Mondher.Toumi@emaud.eu. [2]Department of Public Health, Aix-Marseille University, 27 Boulevard Jean Moulin, Marseille, 13385, France. Mondher.Toumi@emaud.eu.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:432 今日访问量:0 总访问量:413 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)